BioCardia raises $4.4M to extend cash runway into 2027 and support Japan PMA submission
What's the deal? BioCardiaDealroom has a profile for this one. Try Dealroom →, a Sunnyvale-based medical device company, has raised $4.4 million by selling roughly 3.5 million shares at an average price of $1.279 each. The shares were sold through an at-the-market (ATM) offering agreement with H.C. WainwrightDealroom has a profile for this one. Try Dealroom → & Co., with proceeds earmarked to extend the company's cash runway into Q1 2027.
The financing is designed to carry BioCardia through its planned submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its lead asset, CardiAMP Cell Therapy. The company expects to file that submission in Q4 2026.
Why now? BioCardia needed to shore up its balance sheet ahead of a critical regulatory milestone. Without fresh capital, the company risked running low on cash before it could file for approval in Japan — a market that could unlock its first commercial revenue.
If all outstanding warrants from previous financings are exercised for cash, BioCardia says its runway would stretch well beyond PMDA approval and into the start of commercial sales.
What could go wrong? The raise is modest. At $4.4 million, BioCardia has bought itself roughly three additional quarters of runway — not much margin for error if the PMDA submission slips or the review process drags on.
The company's own filings flag risks around liquidity, fundraising, and clinical progress. If warrants go unexercised and no further capital comes in, BioCardia could face another dilutive raise at a time when its share price offers little cushion. Shares traded just above a dollar at the offering price.
The signal: BioCardia sits at the early growth stage, according to Dealroom, yet it is resorting to an ATM programme through H.C. Wainwright — a firm known for facilitating micro-cap life-sciences raises — rather than a conventional venture or crossover round. That financing profile underscores how narrow the capital pipeline remains for pre-revenue medtech companies pursuing single-market regulatory bets, even when the pathway, like Japan's conditional approval route, is designed to accelerate commercialisation.
Read more: Minichart
Image: Cardiac fibroblasts for regenerative myocardial therapy, by Chen W, Bian W, Zhou Y and Zhang J (CC BY 4.0, via Wikimedia Commons).
